-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Guillain-Barre Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANX-005 in Guillain-Barre Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Guillain-Barre Syndrome Drug Details: ANX-005 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empasiprubart in Delayed Graft Function (DGF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empasiprubart in Delayed Graft Function (DGF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empasiprubart in Delayed Graft Function (DGF) Drug Details: ARGX-117...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empasiprubart in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empasiprubart in Dermatomyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empasiprubart in Dermatomyositis Drug Details: ARGX-117 (PRO-02) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANX-005 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Amyotrophic Lateral Sclerosis Drug Details: ANX-005 is under development...
-
Product Insights
Sillans la Cascade Solar PV Park
Sillans la Cascade Solar PV Park is a solar PV project located in Provence-Alpes-Cote dAzur, France. The project is owned by ENGIE Green France SAS and was developed by Solaired040. The project came online in 2021. Empower your strategies with our Sillans la Cascade Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS-0159 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS-0159 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS-0159 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: CS-0159 is...
-
Company Insights
Innovation and Patenting activity of Cascades Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cascades Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS-0159 in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS-0159 in Primary Sclerosing Cholangitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS-0159 in Primary Sclerosing Cholangitis Drug Details: CS-0159 is under development...
-
Company Insights
Innovation and Patenting activity of Boise Cascade Co Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Boise Cascade Co Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...